CD8A and neoplasm: In vivo, RRx-001 significantly suppressed tumor growth (p < 0.001), reduced tumor weight, enhanced infiltration of CD4+ and CD8+T cells, increased M1 macrophage polarization, and downregulated PD-L1 expression.